Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells $48,872.50 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 1,730 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $28.25, for a total transaction of $48,872.50. Following the completion of the transaction, the insider directly owned 78,995 shares in the company, valued at $2,231,608.75. This trade represents a 2.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Performance

CSTL opened at $30.47 on Friday. The stock has a market capitalization of $930.86 million, a price-to-earnings ratio of -46.17 and a beta of 0.98. The company has a fifty day moving average of $23.55 and a 200 day moving average of $26.16. Castle Biosciences, Inc. has a fifty-two week low of $17.72 and a fifty-two week high of $44.28. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.85 and a current ratio of 6.04.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.34. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. The business had revenue of $99.86 million for the quarter, compared to analysts’ expectations of $86.23 million. As a group, sell-side analysts forecast that Castle Biosciences, Inc. will post -1.29 earnings per share for the current fiscal year.

Castle Biosciences News Roundup

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: BTIG raised its price target to $44 from $40 and maintained a “buy” rating. The higher target reflects confidence in Castle Biosciences’ molecular-diagnostics growth outlook and suggests meaningful upside from recent trading levels. BTIG raises Castle Biosciences price target
• Positive Sentiment: Castle Biosciences’ latest quarterly results significantly exceeded expectations. Revenue reached $99.86 million versus the $86.23 million consensus estimate, while the per-share loss was $0.07 compared with the expected $0.41 loss. The company remains unprofitable, but the revenue growth and narrower loss reinforce the improving operating outlook.
• Neutral Sentiment: Institutional investors and hedge funds continue to hold approximately 92.6% of Castle Biosciences’ outstanding shares. Recent position increases by firms including AQR Capital Management, Amundi and Legal & General may provide some institutional support, although these ownership changes are not necessarily a near-term catalyst.
• Negative Sentiment: Several insiders reported sizable stock sales. Derek J. Maetzold sold 39,016 shares for roughly $1.21 million in transactions on August 4–5, while COO Kristen Oelschlager sold 8,586 shares for about $256,000. Tobin W. Juvenal also disclosed a 1,730-share sale worth approximately $49,000. The sales reduce insider ownership and could weigh on sentiment after the stock’s recent advance, although the transactions were executed under pre-arranged Rule 10b5-1 plans, making them a less definitive bearish signal. Castle Biosciences insider sales filing

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CSTL. Amundi boosted its holdings in shares of Castle Biosciences by 15,811.5% in the 1st quarter. Amundi now owns 4,137 shares of the company’s stock worth $79,000 after purchasing an additional 4,111 shares during the period. AQR Capital Management LLC lifted its position in Castle Biosciences by 548.9% in the first quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock worth $2,743,000 after buying an additional 115,907 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Castle Biosciences by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock worth $309,000 after buying an additional 655 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in Castle Biosciences by 10,592.0% during the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after buying an additional 2,648 shares during the period. Finally, Legal & General Group Plc boosted its stake in Castle Biosciences by 34.7% during the second quarter. Legal & General Group Plc now owns 34,908 shares of the company’s stock worth $713,000 after buying an additional 8,992 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on CSTL. BTIG Research increased their price target on Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research note on Monday. Zacks Research downgraded Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 26th. Robert W. Baird set a $36.00 price objective on Castle Biosciences in a report on Friday, July 31st. Wall Street Zen upgraded Castle Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Weiss Ratings raised shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.